Cibc World Market Inc. Makes New $14.34 Million Investment in DENTSPLY SIRONA Inc. $XRAY

Cibc World Market Inc. bought a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,351,619 shares of the medical instruments supplier’s stock, valued at approximately $14,341,000.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of DENTSPLY SIRONA during the second quarter worth approximately $283,405,000. Southpoint Capital Advisors LP purchased a new position in DENTSPLY SIRONA in the 1st quarter valued at $116,000,000. AQR Capital Management LLC lifted its holdings in DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock valued at $211,470,000 after purchasing an additional 6,970,086 shares in the last quarter. Armistice Capital LLC boosted its stake in DENTSPLY SIRONA by 1,044.0% during the 3rd quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier’s stock worth $72,790,000 after purchasing an additional 5,234,587 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in DENTSPLY SIRONA during the 2nd quarter worth $47,780,000. 95.70% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Brian T. Gladden acquired 9,985 shares of DENTSPLY SIRONA stock in a transaction dated Monday, June 15th. The shares were acquired at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the purchase, the director owned 61,849 shares in the company, valued at approximately $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian P. Mckeon purchased 10,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were bought at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director owned 10,000 shares in the company, valued at $101,200. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 35,160 shares of company stock worth $351,179 in the last ninety days. 0.46% of the stock is owned by corporate insiders.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $10.89 on Tuesday. The firm has a market cap of $2.17 billion, a PE ratio of -3.96, a price-to-earnings-growth ratio of 1.38 and a beta of 0.85. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $14.86. The business’s fifty day simple moving average is $12.04 and its 200-day simple moving average is $11.79.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17. The business had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business’s revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.41 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. UBS Group lowered their price target on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Barclays upped their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research note on Monday. Mizuho cut their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Piper Sandler raised their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $13.54.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.